Last $1.43 USD
Change Today +0.02 / 1.42%
Volume 18.0K
TPIV On Other Exchanges
As of 1:02 PM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

tapimmune inc (TPIV) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/14 - $7.00
52 Week Low
10/8/13 - $0.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TAPIMMUNE INC (TPIV)

Related News

No related news articles were found.

tapimmune inc (TPIV) Related Businessweek News

No Related Businessweek News Found

tapimmune inc (TPIV) Details

TapImmune Inc., clinical-stage immunotherapy company, develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious diseases. It is involved in the development of HER2/neu, a vaccine technology, which is in Phase I human clinical trials for the treatment of breast cancer; and Folate Receptor Alpha, a peptide epitope, which is in Phase I human clinical trials for the treatment of breast and ovarian cancer. The company’s products under preclinical stage include Polystart, a nucleic acid–based technology for Her2/neu breast cancer, colorectal cancer, ovarian cancer, and triple negative breast cancer. TapImmune Inc. has a technology option agreement with Mayo Foundation for the evaluation of HER2/neu peptide epitopes, as well as has a research license and option agreement with Crucell Holland B.V. The company was founded in 1999 and is based in Seattle, Washington.

2 Employees
Last Reported Date: 04/17/14
Founded in 1999

tapimmune inc (TPIV) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: $180.0K
Vice President of Development and Member of A...
Total Annual Compensation: $60.0K
Compensation as of Fiscal Year 2013.

tapimmune inc (TPIV) Key Developments

TapImmune Appoints Dr. Keith Knutson to Chair its Scientific Advisory Board

TapImmune, Inc. announced that Dr. Keith Knutson, PhD has been appointed to chair the company's scientific advisory board. Dr. Knutson is Director of the Cancer Vaccines and Immune Therapies Program at the Vaccine & Gene Therapy Institute of Florida. TapImmune has licensed cancer vaccine technologies originating from Dr. Knutson's former laboratory at the Mayo Clinic, which are currently completing phase I clinical trials in breast and ovarian cancer.

TapImmune Seeks Acquisitions

TapImmune, Inc. (OTCPK:TPIV) to seek acquisition. TapImmune, Inc. (OTCPK:TPIV) has filed a shelf registration in the amount of $20 million, $0.4 million of proceeds of the sale of these securities will be used to exercise option to acquire an exclusive license to the Folate Alpha Receptor technology and any remainder for general corporate purposes, which may include funding clinical studies, repayment of existing indebtedness, working capital, capital expenditures, acquisitions and joint ventures.

TapImmune, Inc. Presents at Third Annual Marcum MicroCap Conference, May-29-2014 04:00 PM

TapImmune, Inc. Presents at Third Annual Marcum MicroCap Conference, May-29-2014 04:00 PM. Venue: Grand Hyatt New York, 109 East 42nd Street, New York, NY 10017, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TPIV:US $1.43 USD +0.02

TPIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TPIV.
View Industry Companies

Industry Analysis


Industry Average

Valuation TPIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAPIMMUNE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at